BIOSTAR PHARMACEUTICALS, INC. (NASDAQ:BSPM) Files An 8-K Other EventsItem 8.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
On November 30, 2017, Biostar Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s regaining compliance with NASDAQ continued listing requirement. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01Financial Statements and Exhibits.
Exhibit No. Description
Biostar Pharmaceuticals, Inc. ExhibitEX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Biostar Regains Compliance with NASDAQ Continued Listing Requirement XIANYANG,…To view the full exhibit click
About BIOSTAR PHARMACEUTICALS, INC. (NASDAQ:BSPM)
Biostar Pharmaceuticals, Inc. (Biostar) is a holding company. The Company, through its subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar), and its variable interest entities (VIEs), Shaanxi Aoxing Pharmaceutical Co., Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan), develops, manufactures and markets pharmaceutical products for various diseases and conditions in the People’s Republic of China (PRC or China). The Company offers over-the-counter (OTC) products and prescription-based pharmaceuticals. The Company’s products are sold in approximately 30 provinces in the PRC through a network of over 60 distributors and through approximately 230 sales people. The Company’s products include XinAoxing Oleanolic Acid Capsule, Ganwang Compound Paracetamol Capsule, Tianqi Dysmenorrhea Capsule, Compound Paracetamol and Amantadine Hydrochloride Tablets, Deafness Tongqiao pills and Huangyangning Tablets.